|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
|
JP2004002321A
(ja)
|
2002-03-11 |
2004-01-08 |
Takeda Chem Ind Ltd |
性ホルモン依存性疾患治療剤
|
|
EP1488807A4
(en)
|
2002-03-11 |
2009-07-08 |
Takeda Pharmaceutical |
MEANS FOR THE TREATMENT OF SEXUAL-HORMONE-RELATED DISEASES
|
|
TW200404552A
(en)
|
2002-05-30 |
2004-04-01 |
Akzo Nobel Nv |
Self administered contraception
|
|
GB0418900D0
(en)
*
|
2004-08-24 |
2004-09-29 |
Btg Int Ltd |
Novel salt forms
|
|
EP1890677A4
(en)
*
|
2005-06-16 |
2013-01-30 |
Myriad Genetics Inc |
PHARMACEUTICAL COMPOSITIONS AND THEIR USE
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
EP3804730A1
(en)
|
2006-08-25 |
2021-04-14 |
Janssen Oncology, Inc. |
Compositions for treating cancer
|
|
WO2009009132A1
(en)
|
2007-07-12 |
2009-01-15 |
Cougar Biotechnology, Inc. |
Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
|
|
WO2010091306A1
(en)
|
2009-02-05 |
2010-08-12 |
Tokai Pharmaceuticals |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
|
WO2010091303A1
(en)
|
2009-02-05 |
2010-08-12 |
Tokai Pharmaceuticals |
Novel steroidal cyp17 inhibitors/antiandrogens
|
|
EP2506855A4
(en)
|
2009-11-30 |
2014-07-30 |
Harbor Biosciences Inc |
ANTICARCINOMA COMPOUNDS AND SCREENING METHODS
|
|
JPWO2011083830A1
(ja)
*
|
2010-01-06 |
2013-05-16 |
学校法人関西文理総合学園 |
新規抗がん剤およびそのスクリーニング方法
|
|
AU2011343637A1
(en)
|
2010-12-16 |
2013-05-30 |
Biomarin Pharmaceutical Inc. |
C- 17 -heteroaryl steroidal compounds as inhibitors of CYP11B, CYP17, and/or CYP21
|
|
DE102011083725A1
(de)
|
2011-09-29 |
2013-04-04 |
Bayer Pharma AG |
Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
RS55223B1
(sr)
|
2011-10-10 |
2017-02-28 |
Zach System |
Postupak za dobijanje 17-supstituisanih steroida
|
|
PH12014500943A1
(en)
|
2011-11-30 |
2014-06-30 |
Astrazeneca Ab |
Combination treatment of cancer
|
|
AU2012358219A1
(en)
|
2011-12-22 |
2014-07-10 |
Tokai Pharmaceuticals, Inc. |
Methods and compositions for combination therapy using P13K/mTOR inhibitors
|
|
US20140079636A1
(en)
|
2012-04-16 |
2014-03-20 |
Dinesh U. Chimmanamada |
Targeted therapeutics
|
|
WO2013159225A1
(en)
|
2012-04-23 |
2013-10-31 |
Alphora Research Inc. |
Process for preparation of 17-substituted steroids
|
|
WO2014009434A1
(en)
|
2012-07-11 |
2014-01-16 |
Sandoz Ag |
Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
|
|
WO2014016830A1
(en)
|
2012-07-25 |
2014-01-30 |
Mapi Pharma Ltd. |
Process and intermediates for the preparation of abiraterone acetate
|
|
US20140011992A1
(en)
|
2012-12-20 |
2014-01-09 |
Crystal Pharma, S.A.U. |
Synthesis of abiraterone and related compounds
|
|
SG10201907684PA
(en)
|
2013-01-15 |
2019-10-30 |
Aragon Pharmaceuticals Inc |
Androgen receptor modulator and uses thereof
|
|
WO2014111815A2
(en)
*
|
2013-01-18 |
2014-07-24 |
Cortendo Ab (Publ) |
Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
|
|
MX2015013247A
(es)
|
2013-03-15 |
2016-11-25 |
Iceutica Inc |
Formulacion de acetato de abiraterona.
|
|
US20150246060A1
(en)
|
2013-03-15 |
2015-09-03 |
Iceutica Inc. |
Abiraterone Acetate Formulation and Methods of Use
|
|
EP3035938B1
(en)
|
2013-09-10 |
2020-08-19 |
Madrigal Pharmaceuticals, Inc. |
Targeted therapeutics
|
|
US20150157646A1
(en)
|
2013-09-27 |
2015-06-11 |
Iceutica Inc. |
Abiraterone Steroid Formulation
|
|
ES3063787T3
(en)
|
2013-10-01 |
2026-04-20 |
Novartis Ag |
Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
|
|
AU2015224576A1
(en)
|
2014-03-03 |
2016-09-22 |
Madrigal Pharmaceuticals, Inc. |
Targeted therapeutics
|
|
WO2015143004A1
(en)
|
2014-03-18 |
2015-09-24 |
Synta Pharmaceuticals Corp. |
Targeted therapeutics
|
|
CN104017045B
(zh)
*
|
2014-06-23 |
2016-01-13 |
广州艾格生物科技有限公司 |
甾体cyp17抑制剂的新型药物前体及其应用、制备方法
|
|
US9937259B2
(en)
|
2014-06-27 |
2018-04-10 |
Zhuhai Beihai Biotech Co., Ltd. |
Abiraterone derivatives and non-covalent complexes with albumin
|
|
EP3193857A4
(en)
|
2014-09-18 |
2018-04-11 |
Iceutica Inc. |
Abiraterone acetate formulation and methods of use
|
|
CN104356191A
(zh)
|
2014-09-29 |
2015-02-18 |
上海延安药业（湖北）有限公司 |
阿比特龙单琥珀酸酯及其制备方法
|
|
TWI641616B
(zh)
|
2014-11-28 |
2018-11-21 |
四川海思科製藥有限公司 |
阿比特龍衍生物及其製備方法和醫藥用途
|
|
CN104447394B
(zh)
*
|
2014-12-17 |
2017-01-18 |
成都傲飞生物化学品有限责任公司 |
一种乌苯美司的新型合成工艺
|
|
CN104710499A
(zh)
|
2015-02-15 |
2015-06-17 |
重庆医药工业研究院有限责任公司 |
一种丙酸阿比特龙的晶型及其制备方法
|
|
US10265329B2
(en)
*
|
2015-03-06 |
2019-04-23 |
The Cleveland Clinic Foundation |
Altering steroid metabolism for treatment of steroid-dependent disease
|
|
ES2954596T3
(es)
|
2015-12-23 |
2023-11-23 |
Univ British Columbia |
Profármacos unidos a lípidos
|
|
JP6842474B2
(ja)
|
2016-02-02 |
2021-03-17 |
深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． |
ステロイド系化合物、当該化合物を含む組成物及びその使用
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
WO2018071544A1
(en)
|
2016-10-11 |
2018-04-19 |
Zhuhai Beihai Biotech Co., Ltd. |
Abiraterone derivative and formulations thereof
|
|
CN106977577A
(zh)
|
2017-04-21 |
2017-07-25 |
湖南师范大学 |
两类阿比特龙衍生物的合成
|
|
JP2022523704A
(ja)
|
2019-01-25 |
2022-04-26 |
シェンチェン・ファーマシン・カンパニー・リミテッド |
医薬組成物
|
|
JP7644713B2
(ja)
*
|
2019-03-06 |
2025-03-12 |
プロペラ セラピューティクス インコーポレイテッド |
アビラテロンプロドラッグ
|
|
JP2022525425A
(ja)
|
2019-03-18 |
2022-05-13 |
ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー |
アビラテロン－環状オリゴマー薬学的製剤ならびにその形成方法および投与方法
|
|
CN116490165A
(zh)
|
2020-09-02 |
2023-07-25 |
普洛佩拉治疗公司 |
阿比特龙前药
|
|
CN113929727A
(zh)
|
2020-09-28 |
2022-01-14 |
南京易腾药物研究院有限公司 |
阿比特龙酯类衍生物及其制备方法和应用
|
|
CN117120034A
(zh)
|
2021-02-15 |
2023-11-24 |
普洛佩拉治疗公司 |
阿比特龙前药
|
|
JP2024533332A
(ja)
|
2021-09-08 |
2024-09-12 |
プロペラ セラピューティクス インコーポレイテッド |
経口アビラテロン製剤
|